CCXI On Other Exchanges

chemocentryx inc (CCXI) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CHEMOCENTRYX INC (CCXI)

Related News

No related news articles were found.

chemocentryx inc (CCXI) Related Businessweek News

No Related Businessweek News Found

chemocentryx inc (CCXI) Details

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis. The company is also developing Avacopan for the treatment of patients with complement 3 glomerulopathy and hidradenitis suppurativa. In addition, the company is developing CCX140, an inhibitor of the chemokine receptor known as CCR2, which has completed a Phase II clinical trial in diabetic nephropathy and is being developed for patients with focal segmental glomerulosclerosis. Further, it has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases, and in cancer. The company was founded in 1997 and is headquartered in Mountain View, California.

76 Employees
Last Reported Date: 03/11/19
Founded in 1997

chemocentryx inc (CCXI) Top Compensated Officers

Founder, President, CEO & Chairman
Total Annual Compensation: $909.2K
Executive VP, Chief Financial & Administrativ...
Total Annual Compensation: $656.7K
Senior VP & Head of Pharmaceutics
Total Annual Compensation: $465.3K
Senior VP, Chief Business Officer & Treasurer
Total Annual Compensation: $546.4K
Compensation as of Fiscal Year 2018.
chemocentryx inc
Chemocentryx, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019

ChemoCentryx, Inc. announced earnings results for the first quarter ended March 31, 2019. For the first quarter, the company announced operating income was USD 12.528 million compared to USD 9.856 million a year ago. Net loss was USD 11.949 million compared to USD 9.417 million a year ago. Basic loss per share was USD 0.23 compared to USD 0.19 a year ago.

ChemoCentryx, Inc. to Report Q1, 2019 Results on May 06, 2019

ChemoCentryx, Inc. announced that they will report Q1, 2019 results at 5:00 PM, Eastern Standard Time on May 06, 2019

ChemoCentryx, Inc., Q1 2019 Earnings Call, May 06, 2019

ChemoCentryx, Inc., Q1 2019 Earnings Call, May 06, 2019


The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

CCXI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CCXI.
View Industry Companies

Industry Analysis


Industry Average

Valuation CCXI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 10.5x
Price/Book 6.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.8x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact CHEMOCENTRYX INC, please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at